Skip to contentC
China Pharma Holdings, Inc.
C
CPHIChina Pharma Holdings, Inc. Q2 2017 · 10-Q
Revenue$2.92M$2.92M−17.6% vs Q2 2016 Net Income-$2.29M-$2.29MN/M vs Q2 2016 EPS Diluted-$0.05-$0.05N/M vs Q2 2016 Gross Profit$648,357+34.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
China Pharma Holdings, Inc. · CIK 1106644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$783,342N/M Free Cash Flowderived-$808,522N/M Margins · derivedGross margin22.2%+8.6 pt vs Q2 2016
Operating margin-73.1%−10.3 pt vs Q2 2016
Net margin-78.4%−9.2 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 14, 2017 · 45 d after period end